Moreover, cases of patients with psoriasis or other chronic inflammatory systemic diseases treated with IL-17A inhibitors, IL-12/23 inhibitors, IL-23 inhibitors or TNF-α inhibitors developing eczematous paradoxical reactions, as well as paradoxical psoriasis, have been reported (15, 17). This evidence concerns the gene IL17A and psoriasis.